Bayesian network analyses of resistance pathways against efavirenz and nevirapine
暂无分享,去创建一个
D. Katzenstein | R. Shafer | M. Soares | P. Harrigan | A. Vandamme | K. Deforche | R. Camacho | K. Van Laethem | R. Kantor | Zehave Grossman
[1] J. Corbeil,et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy , 1994, Journal of virology.
[2] M. Wainberg,et al. Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1. , 1997, Nucleic acids research.
[3] P. Boyer,et al. A Mutation at Position 190 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Interacts with Mutations at Positions 74 and 75 via the Template Primer , 1998, Antimicrobial Agents and Chemotherapy.
[4] Nir Friedman,et al. Data Analysis with Bayesian Networks: A Bootstrap Approach , 1999, UAI.
[5] Martine Peeters,et al. Genetic Diversity of Protease and Reverse Transcriptase Sequences in Non-Subtype-B Human Immunodeficiency Virus Type 1 Strains: Evidence of Many Minor Drug Resistance Mutations in Treatment-Naive Patients , 2000, Journal of Clinical Microbiology.
[6] D I Stuart,et al. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. , 2000, Structure.
[7] Zehava Grossman,et al. Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B , 2001, AIDS (London).
[8] D. Katzenstein,et al. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy , 2001, AIDS.
[9] K. Ariyoshi,et al. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients , 2001, AIDS.
[10] A. Vandamme,et al. A Genotypic Drug Resistance Interpretation Algorithm that Significantly Predicts Therapy Response in HIV-1-Infected Patients , 2001, Antiviral therapy.
[11] K. Hertogs,et al. Testing Genotypic and Phenotypic Resistance in Human Immunodeficiency Virus Type 1 Isolates of Clade B and Other Clades from Children Failing Antiretroviral Therapy , 2002, Journal of Clinical Microbiology.
[12] Robert W. Shafer,et al. Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance , 2002, Clinical Microbiology Reviews.
[13] M. Wainberg,et al. Multiple Effects of the M184V Resistance Mutation in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 , 2003, Clinical Diagnostic Laboratory Immunology.
[14] Kaneo Yamada,et al. Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection. , 2003, Journal of acquired immune deficiency syndromes.
[15] M. Wainberg,et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors , 2003, AIDS.
[16] B. Canard,et al. The Y181C Substitution in 3′-Azido-3′-deoxythymidine-resistant Human Immunodeficiency Virus, Type 1, Reverse Transcriptase Suppresses the ATP-mediated Repair of the 3′-Azido-3′-deoxythymidine 5′-Monophosphate-terminated Primer* , 2003, Journal of Biological Chemistry.
[17] J. Schapiro,et al. Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C , 2004, AIDS.
[18] Ronald J Bosch,et al. Genetic correlates of efavirenz hypersusceptibility , 2004, AIDS.
[19] J. Schapiro,et al. Antiretroviral Drug Resistance in Non-Subtype B HIV-1, HIV-2 and Siv , 2004, Antiviral therapy.
[20] Tommy F. Liu,et al. HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. , 2005, The Journal of infectious diseases.
[21] Tulio de Oliveira,et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences , 2005, Bioinform..
[22] Yves Moreau,et al. Analysis of HIV-1 pol sequences using Bayesian Networks: implications for drug resistance , 2006, Bioinform..
[23] Klaus Korn,et al. The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Subtypes , 2006, Journal of acquired immune deficiency syndromes.
[24] S. Lo Caputo,et al. Impact of unreported HIV‐1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non‐nucleoside inhibitors , 2006, Journal of medical virology.
[25] Christos J. Petropoulos,et al. The K101P and K103R/V179D Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Resistance to Nonnucleoside Reverse Transcriptase Inhibitors , 2006, Antimicrobial Agents and Chemotherapy.
[26] Thomas Lengauer,et al. Involvement of Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutations in the Regulation of Resistance to Nucleoside Inhibitors , 2006, Journal of Virology.
[27] Hannah Green,et al. Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase , 2007, AIDS.
[28] Thomas Lengauer,et al. Characterization and Structural Analysis of Novel Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Involved in the Regulation of Resistance to Nonnucleoside Inhibitors , 2007, Journal of Virology.
[29] Anne-Mieke Vandamme,et al. Antiretroviral resistance in different HIV-1 subtypes: impact on therapy outcomes and resistance testing interpretation , 2007, Current opinion in HIV and AIDS.
[30] D. Richman,et al. Update of the drug resistance mutations in HIV-1: 2007. , 2007, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[31] Susan Olender,et al. Advances in antiretroviral therapy. , 2009, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[32] D. Richman,et al. 2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.